|
1.
|
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. MedStar authors:
Year: 2018
Citation: - The Lancet Diabetes & Endocrinology. 6(4):275-286, 2018 04.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andreassen C, Aroda VR, Lingvay I, Ludemann J, Navarria A, Pratley RE, SUSTAIN 7 investigators, Viljoen A
|
|
2.
|
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. MedStar authors:
Year: 2014
Citation: - Diabetes Care. 37(6):1706-11, 2014 Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D
|